Corticosteroids for Dengue – Why Don't They Work?

BACKGROUND: Dysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue. FINDINGS: In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Hanh Tien, Nguyen, Than Ha Quyen, Vu, Tuan Trung, Farrar, Jeremy, Hoang, Truong Long, Dong, Thi Hoai Tam, Ngoc Tran, Van, Phung, Khanh Lam, Wolbers, Marcel, Whitehead, Stephen S., Hibberd, Martin L., Wills, Bridget, Simmons, Cameron P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861232/
https://www.ncbi.nlm.nih.gov/pubmed/24349598
http://dx.doi.org/10.1371/journal.pntd.0002592
Descripción
Sumario:BACKGROUND: Dysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue. FINDINGS: In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels. CONCLUSION: The inability of prednisolone treatment to markedly attenuate the host immune response is instructive for planning future therapeutic strategies for dengue.

Ejemplares similares